A MMP-13 selective inhibitor (Cmpd-1), which was identified from a panel of small molecule pyrimidinetrione-based inhibitors (132), was shown to inhibit osteolytic damage and reduce primary tumor growth in a human breast cancer xenograft model of TNBC using MDA-MB-231 cells, suggesting that MMP-13 selective inhibitors reduce tumor-induced bone osteolysis (133). Here, MMP13 is linked to neoplasm.